VIRAL VECTOR AND PLASMID DNA TESTING SERVICES MARKET ANALYSIS

Viral Vector And Plasmid Dna Testing Services MarketSize and Trends

Global viral vector and plasmid DNA testing services market is estimated to be valued at US$ 234.3 million in 2023 and is expected to exhibit a CAGR of 25.8% during the forecast period (2023-2030).

Figure 2. Global Viral Vector and Plasmid DNA Testing Services Market Value (US$ Million), By Region, 2023

Global Viral Vector and Plasmid DNA Testing Services Market- Segmentation

Global viral vector and plasmid DNA testing services market report is segmented into by service type, by end user and by region.

Based on Service Type, the market is segmented into safety, genetic characterization, purity, identity and potency. Out of which, safety segment is expected to hold a dominant position in the global viral vector and plasmid DNA testing services market during the forecast period, owing to increasing number of inorganic growth strategies such as collaboration and others.

Based on End User, the market is segmented into pharmaceutical and biotechnology industries and research organizations. Out of which, pharmaceutical and biotechnology industries segment is expected to dominate the market over the forecast period, owing to increasing research and development activities using viral vector and plasmid DNA for various therapeutic applications such as oncology and others.

Based on Region, global viral vector and plasmid DNA testing services market is segmented into North America, Latin America, Europe, Middle East, Asia Pacific, and Africa. Out of which, North America is expected to dominate the market over the forecast period, due to increasing inorganic growth strategies such as agreement, partnership and others by key players in the region.

Global Viral Vector and Plasmid DNA Testing Services Market- Cross Sectional Analysis

Among service type, safety segment held a dominant position in North America region over the forecast period due to increasing number of inorganic growth strategies such as collaboration and others by the market players for product development. For instance, in In May 2020, AGC Biologics., AGC Biologics, a contract development manufacturing company, and Takara Bio, a biotechnology company, collaborated in order to develop a prophylaxis COVID-19 vaccine candidate. Under this agreement, AGC Biologics will manufacture the plasmid DNA intermediate for the vaccine.